Marc Silver, MD
Cardiovascular Disease · Chandler, AZNPI 1992818520
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $161,500 of the $173,492 with a category attached, or 93.1%. Daxor Corporation accounts for 89.9% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $79,997, more than ten times the $647 reported in 2019. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 51 payments — averaging $3401.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daxor Corporation$156K
- Impulse Dynamics (USA) Inc.$16K
- Medicure Pharma Inc.$615
- BD$172
- Abiomed$162
- Alnylam Pharmaceuticals Inc.$155
- plus $464 from 8 others
Across 2 payments — averaging $820.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2K
What the payments were for
- Consulting fees$161,50093%
- Speaking & faculty fees$8,5095%
- Travel & lodging$1,5841%
- Food & beverage$1,8801%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daxor Corporation | 13 | $156,000 |
| Impulse Dynamics (USA) Inc. | 21 | $15,924 |
| Medicure Pharma Inc. | 2 | $615 |
| BD | 1 | $172 |
| Abiomed | 2 | $162 |
| Alnylam Pharmaceuticals Inc. | 1 | $155 |
| Daiichi Sankyo Inc. | 2 | $133 |
| Cardiac Dimensions, Inc. | 1 | $90 |
| Scpharmaceuticals Inc. | 1 | $75 |
| Livanova USA, Inc. | 1 | $41 |
| AstraZeneca | 2 | $38 |
| Pfizer | 2 | $36 |
| Boston Scientific | 1 | $32 |
| Picard Medical Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BVA-100$156,000
- OPTIMIZER$17,308
- OPTIMIZER SMART SYSTEM$5,000
- ReDS$615
- Impella$127
- INJECTAFER$113
How this compares
$173,492 in reported general payments places this provider in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 23 | $871,262 |
| VyndaqelTafamidis Meglumine | 11 | $245,655 |
| EntrestoSacubitril/Valsartan | 31 | $42,327 |
| EliquisApixaban | 15 | $20,505 |
| JardianceEmpagliflozin | 22 | $18,817 |
| Carvedilol | 84 | $955 |
| Isosorbide Mononitrate | 30 | $826 |
| Torsemide | 37 | $797 |
| Metoprolol Succinate | 38 | $629 |
| Potassium Chloride | 19 | $602 |
| Furosemide | 33 | $240 |
| Spironolactone | 56 | $220 |
| Lisinopril | 18 | $64 |
| Atorvastatin Calcium | 11 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $36 | $1,137,42249 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Chandler
- Gautam KediaChandler$18K
- Akarsh ParekhChandler$15K
- Ashish GuptaPhoenix$1.1M
- Rajkumar SugumaranPhoenix$957K
- Krishnaswami VijayaraghavanScottsdale$927K
- Steven MottlTucson$340K
- Paul UnderwoodScottsdale$259K
- Omar WaniFlagstaff$244K
- Robert BurkeScottsdale$207K
- Andrew KaplanMesa$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.